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Abstract
Background
Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) coinfection is a major
global health problem especially among people who inject drugs (PWID), with significant
clinical implications. Mathematical models have been used to great effect to shape HIV
care, but few have been proposed for HIV/HCV.
Methods
We constructed a deterministic compartmental ODE model that incorporated layers for HIV
disease progression, HCV disease progression and PWID demography. Antiretroviral ther-
apy (ART) and Methadone Maintenance Therapy (MMT) scale-ups were modeled as from
2016 and projected forward 10 years. HCV treatment roll-out was modeled beginning in
2026, after a variety of MMT scale-up scenarios, and projected forward 10 years.
Results
Our results indicate that scale-up of ART has a major impact on HIV though not on HCV bur-
den. MMT scale-up has an impact on incidence of both infections. HCV treatment roll-out
has a measurable impact on reductions of deaths, increasing multifold the mortality reduc-
tions afforded by just ART/MMT scale-ups.
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Conclusion
HCV treatment roll-out can have major and long-lasting effects on averting PWID deaths on
top of those averted by ART/MMT scale-up. Efficient intervention scale-up of HCV alongside
HIV interventions is critical in Vietnam.
Introduction
Hepatitis C Virus (HCV) afflicts 150 million people globally, the majority of whom are people
who inject drugs (PWID) living in Asia and Africa [1]. Coinfection with human immunodefi-
ciency virus (HIV) occurs in 5-10 million people [2, 3]. Coinfection dynamics are complex at
within- and between-host levels, as the two pathogens share a transmission route and each
pathogen can speed the disease progression of the other [4, 5]. Due to the challenges of navi-
gating two chronic infections and their complex interactions, very few models thus far have
looked at modeling HIV-HCV co-epidemics explicitly [6–8]. Past models of HIV and HCV
mono-infection have been instrumental in gaining deeper understanding into infection
dynamics, e.g. estimation of the basic reproduction number (R0), and predicting the impact of
interventions such as Pre-Exposure Prophylaxis (PrEP) and Test-and-Treat (e.g. [9–12]). HIV
modeling studies that focus on PWID have explored the impact of harm reduction strategies
such as needle-and-syringe programs (NSP) and methadone maintenance therapy (MMT) on
the HIV epidemic among PWID, and found that gains in terms of infections and deaths
averted can be substantial with adequate scale-up [13, 14]. The HIV and HCV co-epidemics
around the globe are fueled by the underlying problem of injection drug use, so our study
builds on previous work by incorporating a specific dynamical model in PWID to explore the
potential of both HIV and HCV treatment interventions alongside harm-reduction interven-
tions to assess gains in the HIV and HCV co-epidemic in a specific at-risk community [7, 8,
10, 13, 14].
Assessing HCV treatment in such models is particularly timely and important with the
advent of new, direct-acting antiviral drugs (DAAs). These new drugs have good safety pro-
files, low risks of drug interactions, high tolerability, and can be administered in 12-24 week
courses, in addition to being very potent with>90% cure rates; this makes them better options
than interferon-ribavirin (IFN-RBV) combination therapies that have been in use up until
now [15, 16]. Currently, even in high-income countries, these new drug regimens are often
unaffordable, with prices ranging up to $168,000 for a 24-week course of therapy [17, 18]. In
low- and middle-income countries, where even the $15,000–$20,000 cost of IFN-RBV is too
high for most patients, the DAAs as they are currently priced will not be an implementable
solution. However, Gilead Sciences, the company that manufactures the DAAs sofosbuvir and
ledipasvir, has already implemented reduced-cost treatment in Egypt, offering the 12-week
course for $900 [19]. One aim in this study is to explore the feasibility of a roll-out of HCV
treatment on a long-term time scale, dictated by these manufacturing constraints.
Ho Chi Minh City (HCMC), Vietnam is a setting for which modeling could be particularly
helpful for long-term planning and policy. Estimates of HIV and HCV prevalence are available
for model calibration, and infrastructure exists or is being designed for roll-out of various
interventions. Efficient roll-out of disease interventions in Vietnam is crucial as the funding
landscape is changing from primarily international donation to government funding [20]. The
HIV/AIDS epidemic in Vietnam is unevenly distributed; country-wide prevalence was esti-
mated at 0.45% in 2011 [20], with the majority of cases among PWID, men who have sex with
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men (MSM), and female sex workers (FSW). Home to 9% of Vietnam’s population with a
2015 population estimate of over 8 million, up from just over 6 million in 2005 [21] and an
estimated *17,000–35,000 of the country’s *160,000–336,000 PWID [20, 22], HCMC has an
estimated HIV prevalence 46.1% among PWID [13, 20, 23].
Estimates of HCV prevalence among PWID in Vietnam have ranged up to 75% since the
1990’s [24–28]. Coinfection with HIV and HCV is very common in PWID, with some esti-
mates of the percentage of HIV-infected PWID coinfected with HCV at 100% [25, 27, 28].
Coinfection introduces a series of complications, e.g. HIV speeds the progression rate of HCV,
and HCV can complicate administration of antiretroviral therapy (ART) due to increased risk
of hepatotoxicity [29]. Recent estimates suggest that nearly *90% of HIV-infected individuals
in Vietnam have a CD4 count of<200 cells/μL upon ART initiation [30]. This delayed access
can mean that for coinfected individuals, chronic HCV may have progressed to chronic liver
disease (CLD) (due to increased HCV progression rates in coinfected individuals), which can
compromise gains in life expectancy conferred by ART initiation to an even greater extent
than late ART initiation does in mono-infected patients [31]. In the pre-ART era, AIDS-
related mortality was high enough to mask the effect of liver disease, as HCV-related cirrhosis
and cancer deaths would come later than an HIV-related death. However, as studies in other
populations have shown (e.g. [32]), the scale-up of ART and subsequent reduction in AIDS-
related mortality have revealed the mortality impact of escalated liver disease progression,
with liver disease accounting for 14-18% of non-AIDS deaths in the HIV-infected population
around the globe [31]. Currently, treatment for HCV is not widely available or publicly funded
in Vietnam, though its impact could be substantial [10].
Tackling the underlying problem of injection drug use is a third puzzle piece to address-
ing the HIV-HCV epidemics in Vietnam. Since the 1990s, one of of the main methods of
injection drug use control has been detention of PWID in rehabilitation centers (known as
06 centers) [33], with an estimated 20% of known drug users being detained at any one time
[34]. The “rehabilitation” that occurs in these centers, throughout the country, is largely
punitive and access to either ART or MMT is severely limited and unlikely [35, 36]. Recog-
nizing the low efficacy of this method, the government began supporting access to clean nee-
dles through NSPs in 2006-2007. However, NSPs have remained relatively small-scale and
inaccessible [13, 23, 33, 34]. NSPs have faced some implementation conflicts due to conflicts
with a 2001 law prohibiting possession of drug paraphernalia, and sentiment among law
enforcement that providing paraphernalia encourages drug use [33, 34]. A 2011 evaluation
report on harm reduction efforts indicated a substantial but heterogeneous increase in NSP
coverage across the country between 2005 and 2009. In HCMC, the number of clean needles
per IDU per year (16 needles) remained well below the national target of 200 per PWID per
year [37].
In 2008, a pilot program for MMT was rolled out in Hai Phong and HCMC, with the aim of
reducing the rates of unsafe injecting, and thus HIV transmission and other adverse health
outcomes among PWID. Reports from these pilot programs indicate that they may be quite
efficacious in addressing the injecting drug use epidemic [38].
The aim of this study is to use a mathematical model of HIV, HCV and injecting drug use
in HCMC to predict the impact of proposed future MMT scale-up at the city level, as well as
the impacts of concurrent ART scale-up and potential future HCV treatment roll-out.
Materials and methods
A compartmental deterministic model was created, incorporating levels for HIV and HCV
dynamics, and PWID demography which are briefly described below (Fig 1). This model is a
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novel synthesis of existing standard HIV and HCV models, and harm-reduction interventions.
Equations for all components of the model can be found in Section 5 of S1 File.
PWID demography
The course of an injecting drug user’s life was modeled using three stages (only current and
ex-PWID were included in the model). Persons enter the PWID community at a certain rate
and remain there for the average duration that PWID inject in Vietnam. The rate of entry into
the PWID community is time-dependent and constructed so as to reproduce the estimated
change in the total number of PWID in this setting. During this time, PWID have an increased
death rate due to overdose [39]. Included in this group are PWID in detention centers have
high rates of relapse, and may have poor ART/MMT access [34–36], as well as PWID who tem-
porarily stop using but then relapse. The Ex-PWID compartment includes only those who
have permanently stopped injecting. From the community, PWID can be recruited into
MMT, or can cease injecting (and thus exit the community) spontaneously. PWID in MMT
programs decrease their rates of injecting. However, retention is imperfect and relapse is com-
mon. Assumptions are that MMT increases life expectancy because excess risk of death due to
drug-related complications is ameliorated, and also increases flow into ART programs. The
latter assumption is based on the criterion for MMT initiation that PWIDs should be on ART
(though not all are) or that ART should be started with MMT [20].
HIV natural history model
HIV progression and transmission were modeled using acute, asymptomatic and AIDS
(CD4<200 cells/μL) stages of infection. Susceptible individuals flow into the acute infection
Fig 1. Diagram of model flows. This figure shows a graphical representation of the model pathways. The
model has a layer for each set of dynamics (PWID, HIV, HCV), and each layer is composed of compartments
with flows between them. For example, in the PWID layer, individuals in the active user compartment move
into the ex-PWID and Methadone Maintenance compartments at different rates. Each PWID compartment in
turn is broken up into compartments for each disease stage, so the total number of compartments is number
of PWID compartments multiplied by the number of HIV compartments multiplied by the number of HCV
compartments. Full equations and descriptions can be found in Section 5 of S1 File.
https://doi.org/10.1371/journal.pone.0177195.g001
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state via a hazard function that is based on a weighted estimate of HIV prevalence. Asymptom-
atic infection is distributed over three stages of equal duration, reflecting an Erlang distribu-
tion [40] (see Section 5.1 in S1 File). Individuals initiate ART from each stage of infection at
different rates but individuals who initiate ART when CD4<200 cells/μL have higher death
rates on treatment. Parameter values are reported in Table 1.
ART scale-up in Vietnam began in 2005, so no treatment was included in the model before
then. Treatment coverage rates as reported by National Committee for AIDS Drugs and Pros-
titution Prevention and Control were used (shown in Fig A in S1 File) [20, 30, 41]. A 2010
study conducted by Family Health International (FHI) reported that 60-70% of people on
ART at two clinics in HCMC were current or former PWID, and with VAAC reporting that
60% of HIV infections were among PWID/ex-PWID, this indicates that the treatment rates
are appropriate for PWID [30, 42].
HCV natural history model
HCV progression and transmission were similarly modeled using acute and chronic stages
of infection. Susceptible individuals become acutely infected via a similar hazard function
that is based on an estimate of HCV prevalence weighted for stage of infection and treatment
status, and either clear infection (with or without protective immunity) [43] or move on to
chronic infection. Several studies of reinfection risk (reviewed in Grebely et al [44]) have
contradictory results, but on the whole they indicate that some individuals have protection
against reinfection after spontaneous clearance, so we have chosen to include protection in
the model. There are four stages of chronic infection, aligning with an Erlang distribution fit
to data on HCV progression in PWID with and without HIV [29], and roughly correspond-
ing to the four stages of fibrosis progression [45]. As noted studies including in Di Martino
et al. [29] HCV progression is faster in HIV coinfected individuals. The last stage is all-cause
chronic liver disease, encompassing compensated and decompensated cirrhosis, and hepato-
cellular carcinoma.
Data
Estimates for HCV prevalence among PWID in Vietnam are uniformly high, approaching
90% in major cities [25–28]. In northern Vietnam, a prospective cohort study in 200 young
male active heroin users showed that HCV anti-body prevalence increased linearly from
*30%to * 70% as duration of injection use increased from 10 months to 30 months [25],
while another study in Bac Ninh province found that 229 out of 309 PWID (74%) tested posi-
tive for HCV [27], and a cross-sectional study in Northern Vietnam on PWID entering 06
drug treatment centers reported positive HCV tests among 350 of 455 PWID (77%) [26]. In
southern Vietnam, an earlier study reported 58 out of 67 PWID examined (87%) were posi-
tive for anti-HCV [24], and HCV prevalence in HCMC among PWID recruited into MMT
pilot study in 2008 was 69.7% (n = 498) [38]. Lastly, HCV prevalence estimates among men
who actively inject drugs in HCMC according to sentinel surveillance reports of the Inte-
grated Biological and Behavioral Surveillance (IBBS) from 2006 to 2009 were 71% (63.6-
78.4%, n = 310) [46]. HIV prevalence estimates are from sentinel surveillance reports com-
piled from the 2006 and 2009 IBBS [47, 48]. IBBS is community-based systematic surveil-
lance purposed for collecting information on health status and risk behaviors among high-
HIV risk populations (MSM, commercial sex-workers and PWID). Recruitment was done
by respondent-driven sampling, and information was obtained by one-on-one interviews
and collection of biological samples.
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Table 1. Parameter values.
Parameter
Name
Description Value Range Source Comments
PWID
parameters
μI baseline death rate of PWID 1/24.4 yr−1 [.026,
.064]
[49]
μX baseline death rate of ex-PWID 1/36 yr−1 [48] average age of PWID 34; average male life
expectancy in VN 70.2 years
Λ excess recruitment rate of new PWID 1.11 [50] multiplier times growth rate based on μ terms
ρ dropout rate/year of PWID in MMT 1/7.69 [.05, .25] [38] calculated by fitting to dropout data
γD 1/duration of drug use career 1/13 yr−1 [48]
η 1/duration initial MMT phase 1/2 yr−1
ν recruitment rate into MMT clinic 0.003 yr−1 [10] 1.3% PWID reached by MMT
mR reduction in risk among PWID entering MMT 0.8 [.4, .9] [38, 51]
HIV
parameters
θ Progression rate from acute stage (1/duration) 4 yr−1 [52]
cP, cI, cA, cT Transmission-weighting of prevalence term by
stage of infection
25, 1, 7, .04 [52] Primary, Asymptomatic, AIDS, Treated
γH 1/duration of each stage of infection, including
CD4<200 to death
1/2.3 yr−1 [40]
αI treatment rate those with CD4200 .0021 yr−1 [20, 41] †
αA treatment rate those with CD4<200 See Sections 1 and
7 in S1 File
[20, 41]
δI excess death-rate for Treated, early initiation
(including 10% LTF)
1/21 yr−1 [53, 54]
δA excess death-rate for Treated, late initiation
(including 10% LTF)
1/13.4 yr−1 [53, 54]
mT increase in treatment rates when linked into
MMT
2 [1, 5] [38]
HCV
parameters
κ proportion of acutely infected individuals who
clear infection
0.25 [.15, .4] [55]
κHIV proportion of acutely infected individuals who
clear infection- HIV coinfected
0.1 .15-.5 [55]
ϕ proportion of cleared infections acquiring
immunity
.1 EO
ϕHIV proportion of cleared infections acquiring
immunity- HIV coinfected
.01 EO
γA 1/duration of Acute infection 2 yr−1 [55]
γC progression rate through each stage of
infection
.104 yr−1 [.05,
.125]
[29, 45]
γCHIV acceleration of progression among HIV+ 2 [1.4, 3] [29, 45]
δL additional death rate due to chronic liver
disease
1/4 yr−1 [1/4, 1] [45]
 HCV Treatment Efficacy 90% [87%,
93%]
[16, 56]
† In 2009 and 2010, roughly 12% of people initiating ART had CD4200 [30]. Applying these percentages to number of people initiating ART in total for
those years yields 1249 and 1297, out of an estimated 175510 and 176561 PLHIV with CD4200. A rough estimate of the rate is this.7%/year or roughly 1/
20th of the rate at which PLHIV with CD4 <200 initiate ART.
EO = expert opinion
https://doi.org/10.1371/journal.pone.0177195.t001
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Fitting
The model was calibrated to data on HIV and HCV prevalence using Maximum Likelihood
Estimation (MLE) with a binomial likelihood function. We varied the parameters governing
the hazard functions for HIV and HCV acquisition, initial HIV prevalence, and risk-reduction
due to NSP so the model outputs reproduced the HIV and HCV prevalence trends observed in
the data. Parameters governing the hazard functions were allowed to vary between the pre-
and post-ART availability time periods, with the impact of ART availability beginning between
2005 and 2007. Initial seeds were drawn from estimates for the range of each parameter, and
the parameter space was explored using the Nelder-Mead algorithm with MATLAB 2015b’s
fminsearch function (See Sections 5.1.1, 5.3.1 and 6 in S1 File for further details).
Interventions
The initial interventions to be implemented in this model involve planned scale-up of MMT
coverage and ART coverage. Each scale-up is implemented at varying coverage levels and
rates, individually and in tandem. The ART and MMT percentages represent percentage of
PWID newly initiated on the intervention each year. These initial interventions are projected
out for a 10-year period from 2017 to 2027, and then incidence of each infection and deaths
are compared, to assess relative impact.
After the initial interventions are run for 10 years, HCV treatment coverage is implemented
at varying levels and projected out a further 10 years from 2027–2037 on top of maximum pre-
vious scale up of ART and MMT coverage (80% and 50%). This 10-year delay was chosen in
relation to when the patents on new DAAs are likely to expire (2026–2029) rendering the
drugs more affordable [57]. The coverage percentage indicates the proportion of chronic HCV
patients who receive treatment by the end of each chronic stage. If treatment is successful, the
patient will move back into the HCV-negative Susceptible state. There is little known about
whether patients treated with DAAs acquire any protection from reinfection, so we do not
assume that treated individuals acquire any immunity [58]. We do not, however, assume that
patients who have progressed through all stages of fibrosis to CLD recover. There is some evi-
dence that CLD patients treated with DAAs have similar death rates to those left untreated
[59], so we assume similar death rates for treated and untreated CLD patients. The same cover-
age of treatment is provided to all chronically HCV-infected patients (not restricted to those
with chronic liver disease). It is assumed that treatment efficacy is high (around 90%) in line
with estimates of the efficacy of the DAA combinations [16, 56].
Results
Model fits
Our model is able to reproduce the following observed trends in HIV and HCV prevalence:
Fig 2 shows the range of model estimates of prevalence (light-colored swathes) as well as the
best-fitting parameter set output (dashed line) of the model to data. The parameters varied in
the fitting process were coefficients in HIV and HCV hazard functions for incidence (coeffi-
cients changed after advent of ART), initial HIV prevalence, and impact of needle and syringe
programs on the force of infection. Specifically, the β terms represent the density-dependent
transmission probability of each infection. The hazard of infection is proportional to number
of people already infected, and the proportionality constant is given by each β. Table 2 shows
the maximum-likelihood estimates for each fitted parameter along with the 95% univariate
bounds for each individual parameter estimate.
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Interventions
Interventions were each scaled up to their final coverage levels over a five-year period from
2017–2022 and run at that level for a further five years 2022–2027. The plots in Figs 3 and 4
represent the reductions in HIV and HCV incidence, prevalence, and deaths under each type
of intervention. HIV incidence and deaths are impacted by both ART scale-up and MMT
scale-up. For HCV, MMT scale-up has a much more pronounced effect on incidence than
ART scale-up. MMT has the strongest impact on incidence reduction because it stops expo-
sure, targeting both infected and susceptible PWID. It has a greater impact even than ART on
reducing HIV incidence, though ART has a more direct effect reducing HIV deaths. The
Fig 2. Model fit to HIV and HCV prevalence. This figure shows the range of model estimates for HIV (blue) and HCV (green)
prevalence among PWID in the shaded regions, with the estimate from the best-fit parameter set represented by the dashed
line. Data estimates and corresponding confidence intervals to which the model was calibrated are represented by circles and
error bars.
https://doi.org/10.1371/journal.pone.0177195.g002
Table 2. Maximum likelihood estimates of fitted parameters.
Name Best Fit Mean Lower Bound Upper Bound
βHIV0 4.55E-05 8.84E-03 1.92E-122* 2.00E-02
βHIV1 1.74E-01 1.72E-01 1.51E-01 2.08E-01
βHCV1 6.99E-01 7.92E-01 4.99E-01 1.00E+00
Initial HIV prevalence 2.50E-02 1.29E-02 4.99E-107* 2.50E-02
ωns 1.25E-01 2.23E-01 1.31E-02 5.00E-01
Post-ART parameters
ωHIV 5.46E-01 3.97E-01 5.88E-68 8.39E-01
βHCV 6.45E-01 6.56E-01 3.52E-01 1.00E+00
* The lower bound for βHIV0 approaches zero because for some parameter sets, βHIV1 is sufficient to explain HIV prevalence trends, while the lower bound
for initial HIV prevalence approaches zero, because for some parameter sets, βHIV0 is high enough to initiate the epidemic.
https://doi.org/10.1371/journal.pone.0177195.t002
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impact of MMT on deaths from HIV and HCV is indirect: while MMT does have an impact
on overall deaths from overdose, it only impacts deaths from infection by preventing future
infections. With these prevention effects, reductions in deaths from HIV will follow within 10
to 20 years; but reductions in HCV deaths will not appear until longer after scale-up because of
the longer duration of HCV infection. ART, however, will afford a small impact on HCV
deaths due its reduction of the extent to which HIV speeds HCV progression. Combinations
of ART and MMT scale-up have an additive effect on total deaths in the population, with
MMT scale-up contributing to reductions in deaths of otherwise-healthy PWID.
As can be seen in Fig 5, however, even with ART and MMT scale-up, the total number of
deaths per year drops after 10 years of intervention, but the number of deaths due to HCV
per year remains almost constant across interventions. This result suggests that including an
HCV-specific intervention is necessary and may have significant marginal impacts.
Looking another 10 years forward to when high-efficacy DAA therapy for HCV is more
affordable, it can be seen that implementing HCV treatment rollout in conjunction with ART
and MMT scale-ups over the period from 2027-2037 can provide substantial reductions in
deaths in this population. Fig 6 demonstrates that including HCV treatment coverage on top
of MMT and ART scale-ups can double or triple gains in reductions in deaths, indicating that
the marginal benefit of rolling out HCV treatment is large. Even when ART and MMT have
been scaled up at high levels, there are still many deaths not averted.
Fig 3. ART scale-up: Incidence and deaths changes over time. Each panel in this figure shows a plot of reductions in HIV and HCV incidence,
prevalence or deaths with varying ART scale-up, with scale-up percentages representing the proportion of patients newly initiated on ART each year
(See Sections 5 and 7 in S1 File for details).
https://doi.org/10.1371/journal.pone.0177195.g003
Modeling HCV treatment for people who inject drugs in Ho Chi Minh City, Vietnam
PLOS ONE | https://doi.org/10.1371/journal.pone.0177195 May 11, 2017 9 / 17
Discussion and conclusion
In this study, we use a mathematical model of the HIV and HCV co-epidemics in HCMC,
Vietnam to analyze the effect of various interventions on future disease burden and cost-effec-
tiveness of these infections. Our results indicate that scale-up of ART coverage can have an
impact on HIV burden, though very little impact on HCV burden. MMT scale-up, however,
can have an impact on both HIV and HCV incidence levels even at below-optimal coverage.
We examine the impact of DAA therapy for HCV, and we conclude that HCV treatment roll-
out in combination with MMT/ART scale-up has the potential to yield a multi-fold increase in
the total number of deaths averted, compared to MMT/ART scale-up alone. While there has
been extensive modeling work done on HIV and HCV monoinfection, only a small number of
other studies have modeled coinfection. Monoinfection models can provide much insight into
impacts of interventions on each infection e.g. [9, 11] even in highly coinfected populations,
but there are details that they will necessarily miss. For example, only with a coinfection model
is it possible to measure the collateral impact on HCV of treating HIV. Because there are
potentiating effects between the infections, only a model that takes into account both infec-
tions will be able to assess the impact of interventions for one on the other, and assess fully the
impact of interventions such as MMT that target both infections. Additionally, though there
has been little evidence of drug resistance to the new DAAs, its emergence is likely and it prob-
ably will not be independent from HIV status.
Fig 4. MMT scale-up: Incidence and deaths changes over time. Each panel in this figure shows a plot of reductions in HIV and HCV incidence,
prevalence or deaths with varying MMT scale-up with scale-up percentages representing the proportion of patients newly initiated on MMT each year
(See Sections 5 and 7 in S1 File for details).
https://doi.org/10.1371/journal.pone.0177195.g004
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As with many modeling studies, this study has several limitations. Many parameters, such
as transmission probability and impact of NSPs on transmission, are difficult to identify, and
must be estimated using fitting techniques that cannot always account for co-linearity. The
data that we use for calibration are from a variety of sources with varying sample sizes and con-
fidence. However, we perform sensitivity analyses (see Section 2 in S1 File) to demonstrate
that our results are qualitatively robust across parameter sets. We also assume that treated indi-
viduals (except for those who have progressed to chronic liver disease) go back to being sus-
ceptible, when in reality it is likely that those with more severe liver damage still have
increased morbidity. We tested the sensitivity of our model to this assumption by building in
an additional compartment for treated individuals, in which they are cured but can be rein-
fected, and also have a shorter lifespan to account for this additional morbidity due to liver
damage. We found that using this more complex model did not alter any results significantly,
except for a cost analysis as described below and in Section 3 in S1 File. Our study also does
not take into account other groups at high risk of HIV acquisition, e.g. female sex workers
(FSW) and men who have sex with men (MSM). There would likely be spillover effects among
FSW and MSM, as there is some interaction between PWID and these groups. The model
accounts for this in having a force of infection for HIV that is not fully dependent on preva-
lence among PWID, but it is not able to measure changes in burden among these other groups.
However, it seems likely that reducing the HIV burden among PWID would have positive
indirect effects among FSW and MSM, for example among HIV-positive MSM who may be at
risk of sexually transmitted HCV [60].
Our results confirm predictions by Durier et. al. [10] and Martin et. al. [9] that show very
optimistic results for reductions in prevalence and incidence of HCV after roll-out of HCV
Fig 5. ART and MMT scale-up: Reductions in deaths from disease over time. Each bar in this figure shows a plot of reductions in deaths from
disease 10 years after intervention scale-up with varying ART and MMT scale-up.
https://doi.org/10.1371/journal.pone.0177195.g005
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treatment. In addition to extending healthy life expectancy for newly-cured HCV patients,
HCV treatment coverage of coinfected patients insures the gains in life expectancy given by
ART by protecting those patients from liver disease deaths. Our model indicates that ART and
MMT scale-ups, while effective, still leave many deaths not averted unless HCV treatment is
rolled out in tandem. This result holds across varying levels of ART and MMT scale-ups, sug-
gesting that HCV treatment roll-out need not wait until ART and MMT hit optimal levels.
Currently, interferon and ribavirin treatment is prohibitively expensive in Vietnam, has
limited efficacy, and is associated with side effects that can be severe [61]. The new DAAs have
shorter durations and much higher efficacy, but are likewise prohibitively expensive with costs
ranging up to nearly $200,000 [62]. However, the real costs of manufacturing these drugs are
lower. In the future, it may be possible to produce 12-week regimens for $100–$250 [62]. Scal-
ing up of DAA therapy is a challenge for Vietnam, a low middle income country with many
health priorities. However, the political will to expand treatment options for chronic hepatitis
C infection exists: the Vietnamese Ministry of Health recently updated its national guidelines
in September 2016 and added DAAs as alternative options to interferon-based regimens as
alternative options [63]. Generically-made DAA-based regimens such as sofosbuvir and ledi-
pasvir are now available in the clinics for patients who can afford the treatment and cost
approximately $700 to $900 a month for patients [64, 65]. National scaling up of DAA therapy
Fig 6. HCV treatment: Reductions in deaths from disease over time. Each panel in this figure shows a plot of
reductions in deaths from disease 10 years after roll-out of HCV treatment coverage, with maximum previous scale up of
ART and MMT coverage (80% and 50%).
https://doi.org/10.1371/journal.pone.0177195.g006
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will require a political investment, leverage of the country’s extensive infrastructure and skilled
healthcare workforce in HIV, continued scaling up of harm reduction programs for PWID,
and continued efforts to reduce the drug price. This modeling study can provide the data for
which cost-effective analyses can be conducted to guide the national treatment strategies. An
analysis of cost shown in Section 3 in S1 File indicates that cost-per-life-year saved may
decrease with increased HCV treatment coverage. However, unlike the predictions about cases
and deaths averted, this particular result is very sensitive to model structure. We present cost
analyses under three different model structures; when we assume that some proportion of
treated individuals acquire protection from reinfection after treatment, the cost-per-life-year
saved decreases with increasing treatment coverage. However, if we assume treated individuals
can get reinfected at the same rate as susceptible individuals, the number of deaths averted
over a longer period of time goes down and the cost-per-life year saved ends up increasing, as
more people get treated for HCV. This sensitivity indicates that it is important to ascertain
reinfection rates for treated individuals in order to conduct accurate cost-effectiveness
analyses.
In confronting the HIV epidemic in Vietnam, it is vital to take into account the high rates
of HCV coinfection. Scale-up of ART can have significant impact on HIV incidence and
deaths, but does very little for HCV control (though individual patients do benefit from ART
[4]). Scale-up of MMT impacts both HIV and HCV incidence as well as deaths, though it is
crucial for it to be tied to ART access. However, both of these interventions leave much to be
desired in the way of averting HCV deaths, indicating that if HCV treatment programs can be
rolled out in Vietnam, they will have the potential to greatly increase life expectancy gains
beyond what is afforded by MMT and ART scale-up.
MMT scale-up is becoming a reality in Vietnam, with a proposed 20 new clinics opening in
2016, and a goal of reaching 80,000 PWID across the country by the end of 2016 [20]. Studies
thus far have indicated that MMT has good acceptability among PWID, and that retention
rates are high (*90% after 1 year) [38]. MMT has the potential to offer longer life expectancy
to PWID with and without HIV and HCV, and as can be seen in the simulations, the potential
to reduce incidence and deaths significantly.
The Vietnamese government has committed to ART and MMT scale-up efforts, and tre-
mendous progress has been made: as of December 2011, 11 out of 64 provinces have function-
ing MMT programs reaching nearly 7,000 PWID and benefits have been seen, with reduced
family conflicts and crime reported in areas with these programs [20]. These province-level
programs receive the bulk of their funding from PEPFAR, DFID and other international assis-
tance. However, these sources are expected to significantly reduce in the near future due to
global financial concerns, and as Vietnam recently achieved middle-income status [20]. The
Vietnamese government is switching focus from relying on international funding to national
funding and management, and it is crucial to ensure that gains already achieved in HIV care
are not lost, and that future progress can be sustainable [20].
If HCV treatment programs are rolled out in the future, they could also be well incorpo-
rated into existing ART and MMT infrastructure. Targeting coinfected patients for co-treat-
ment is effective for both treatment and prevention, especially if the patients are enrolled in
MMT. Costs may be difficult to control, but building programs into existing clinics and satel-
lite centers may help curb short-term costs for long-term gains.
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